Ural

Each 4 g of Ural contains sodium bicarbonate 1760 mg, anhydrous sodium citrate 630 mg, anhydrous citric acid 720 mg and tartaric acid 890 mg.
It also contains the following excipients: Nature identical lemon flavor oil, terpeneless and sodium saccharin.
Ural consists of formulation and pleasantly flavored granules. When added to water, Ural effervesces and dissolves, forming a clear or orange-colored alkaline solution.

Urinary and gastric alkalinizer.

Urinary alkalinization where indicated: For gout therapy, as urinary alkalinizers to prevent crystallization of urates.
For symptomatic relief of painful urination (dysuria).
For relieving of discomfort in mild urinary tract infection (UTI).
To enhance the action of certain antibiotics especially some sulfonamides.

4-8 g (1-2 sachets) dissolved in cold water 4 times daily. Adults: 4-8 g in half a glass of cold water, 3-4 times daily, taken on an empty stomach after effervescence has subsided. Additional water (approximately ½ glass) should subsequently be ingested.
Children 6-12 years: 4 g in half a glass of cold water, 2-3 times daily, taken on an empty stomach after effervescence has subsided. Additional water (approximately ½ glass) should subsequently be ingested.

Renal failure or hypernatremia; in conjunction with hexamine mandelate or hexamine hippurate therapy because an acidic urine is needed.
Caution is advised in overt and occult cardiac failure. Concomitant use of urinary alkalinizers and quinolone antibiotics should be avoided. Crystalluria may be more likely to occur in alkaline urine.

Ural contains sodium 644 mg/sachet which should be taken into account by those on a low sodium diet.
Ural should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema and preeclampsia.
The clinical condition of the patient should be evaluated and laboratory determinations (eg, serum electrolytes, acid-base balance) obtained periodically during Ural therapy, particularly in patients with renal disease.
Use in pregnancy: Studies regarding the effect of citrates on pregnancy have not been done.
Use in lactation: Caution should be exercised when administered to a nursing mother.

Use in pregnancy: Studies regarding the effect of citrates on pregnancy have not been done.
Use in lactation: Caution should be exercised when administered to a nursing mother.

The tartrate component of Ural may be incompletely absorbed. Because of this, Ural may exert a mild laxative effect. Prolonged and excessive use may cause systemic alkalosis and/or hypernatremia.

General: Alkalinization of the urine due to the use of Ural, theoretically, may result in a decreased therapeutic effect of the following medications: Chlorpropamide, lithium, salicylates and tetracyclines. Alternatively, alkalinization of the urine due to the use of Ural, theoretically, may result in an increased therapeutic effect of the following medications: Amphetamines, ephedrine/pseudoephedrine.
Antacids: Concurrent use of antacids with citrates may result in systemic alkalosis. Concomitant administration of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypernatremia. Concurrent use of aluminum-containing antacids with citrate salts can increase aluminum absorption, possibly resulting in acute aluminum toxicity, especially in patients with renal insufficiency.
Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotoxicity.
Laxatives: Concurrent administration of citrates with laxatives may have an additive effect.

Store at temperatures not exceeding 30°C.

Other Drugs Acting on the Genito-Urinary System

G04BX - Other urologicals ; Used in the treatment of urological problems.

Non-Rx